Tags

Type your tag names separated by a space and hit enter

Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
Scand J Gastroenterol. 2008; 43(9):1128-36.SJ

Abstract

OBJECTIVE

Leptin and adiponectin have been implicated in the pathogenesis and progression of non-alcoholic steatohepatitis (NASH) and chronic hepatitis C (CHC), but little is known about the role of resistin in chronic liver diseases. The objective of this study was to investigate serum levels of the above three adipokines in relation to the etiology of liver disease and to determine their associations with histological severity.

MATERIAL AND METHODS

We prospectively evaluated 146 patients (HBeAg-negative chronic hepatitis B (CHB): 52, CHC: 70, NASH: 24) who consecutively underwent liver biopsy. Detailed epidemiological, anthropometric and laboratory data were recorded. Histological lesions were evaluated blindly according to the Ishak and the Brunt classifications for CHB/CHC and NASH, respectively.

RESULTS

Serum adipokine levels were similar between CHB and CHC patients, while CHB/CHC patients had significantly lower leptin levels compared with NASH patients (8.3+/-7.3 versus 17.6+/-16.6 ng/ml, p=0.012) and higher adiponectin (10.2+/-5.1 versus 7.5+/-4 microg/ml, p=0.018) and resistin levels (7.1+/-2.5 versus 5.7+/-2.8 ng/ml, p=0.016). In CHB/CHC, there was no significant association between steatosis or necroinflammation and levels of adipokines, while the presence of moderate/severe fibrosis (stages 4-6) was associated with higher leptin and adiponectin levels in male but not in female patients and with lower resistin levels irrespective of gender or other factors (adjusted odds ratio=0.788, p=0.035).

CONCLUSIONS

Serum adipokine levels depend on the etiology of liver disease differing between chronic viral hepatitis and NASH, but not between CHB and CHC. In CHB/CHC, resistin levels are independently associated with fibrosis severity, whereas in the association of leptin and adiponectin levels with fibrosis, it seems to be a gender effect.

Authors+Show Affiliations

Second Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital, Athens, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

18609175

Citation

Tsochatzis, Emmanuel, et al. "Serum Adipokine Levels in Chronic Liver Diseases: Association of Resistin Levels With Fibrosis Severity." Scandinavian Journal of Gastroenterology, vol. 43, no. 9, 2008, pp. 1128-36.
Tsochatzis E, Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol. 2008;43(9):1128-36.
Tsochatzis, E., Papatheodoridis, G. V., Hadziyannis, E., Georgiou, A., Kafiri, G., Tiniakos, D. G., Manesis, E. K., & Archimandritis, A. J. (2008). Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scandinavian Journal of Gastroenterology, 43(9), 1128-36. https://doi.org/10.1080/00365520802085387
Tsochatzis E, et al. Serum Adipokine Levels in Chronic Liver Diseases: Association of Resistin Levels With Fibrosis Severity. Scand J Gastroenterol. 2008;43(9):1128-36. PubMed PMID: 18609175.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. AU - Tsochatzis,Emmanuel, AU - Papatheodoridis,George V, AU - Hadziyannis,Emilia, AU - Georgiou,Anastasia, AU - Kafiri,Georgia, AU - Tiniakos,Dina G, AU - Manesis,Emanuel K, AU - Archimandritis,Athanasios J, PY - 2008/7/9/pubmed PY - 2008/10/22/medline PY - 2008/7/9/entrez SP - 1128 EP - 36 JF - Scandinavian journal of gastroenterology JO - Scand. J. Gastroenterol. VL - 43 IS - 9 N2 - OBJECTIVE: Leptin and adiponectin have been implicated in the pathogenesis and progression of non-alcoholic steatohepatitis (NASH) and chronic hepatitis C (CHC), but little is known about the role of resistin in chronic liver diseases. The objective of this study was to investigate serum levels of the above three adipokines in relation to the etiology of liver disease and to determine their associations with histological severity. MATERIAL AND METHODS: We prospectively evaluated 146 patients (HBeAg-negative chronic hepatitis B (CHB): 52, CHC: 70, NASH: 24) who consecutively underwent liver biopsy. Detailed epidemiological, anthropometric and laboratory data were recorded. Histological lesions were evaluated blindly according to the Ishak and the Brunt classifications for CHB/CHC and NASH, respectively. RESULTS: Serum adipokine levels were similar between CHB and CHC patients, while CHB/CHC patients had significantly lower leptin levels compared with NASH patients (8.3+/-7.3 versus 17.6+/-16.6 ng/ml, p=0.012) and higher adiponectin (10.2+/-5.1 versus 7.5+/-4 microg/ml, p=0.018) and resistin levels (7.1+/-2.5 versus 5.7+/-2.8 ng/ml, p=0.016). In CHB/CHC, there was no significant association between steatosis or necroinflammation and levels of adipokines, while the presence of moderate/severe fibrosis (stages 4-6) was associated with higher leptin and adiponectin levels in male but not in female patients and with lower resistin levels irrespective of gender or other factors (adjusted odds ratio=0.788, p=0.035). CONCLUSIONS: Serum adipokine levels depend on the etiology of liver disease differing between chronic viral hepatitis and NASH, but not between CHB and CHC. In CHB/CHC, resistin levels are independently associated with fibrosis severity, whereas in the association of leptin and adiponectin levels with fibrosis, it seems to be a gender effect. SN - 1502-7708 UR - https://www.unboundmedicine.com/medline/citation/18609175/Serum_adipokine_levels_in_chronic_liver_diseases:_association_of_resistin_levels_with_fibrosis_severity_ L2 - http://www.tandfonline.com/doi/full/10.1080/00365520802085387 DB - PRIME DP - Unbound Medicine ER -